BeOne Medicines shared on LinkedIn:
“News for Investors and Media:
BeOne Medicines announces second quarter 2026 financial results and business updates.”
John V. Oyler, Founder, Chairman and CEO at BeOne Medicine, shared on LinkedIn:
“Proud to share BeOne’s Q2 2026 results. It was another solid quarter of execution.
- We delivered total global revenue of $1.7 billion, representing 30% year-over-year growth.
- Net income totaled $237 million with GAAP diluted earnings per ADS of $2.05.
- Gross margin improved to 90% from approximately 87% in the prior year.
These results would not be possible without the dedication of our 12,000+ purpose-driven colleagues around the globe.
Together, we are how the world stops cancer.”